Anti-human T-lymphocyte immunoglobulin interactions
Checked as Antilymphocyte immunoglobulin (horse) in this data source.
Full monograph for Anti-human T-lymphocyte immunoglobulinCheck it against another medicine
Medicines
38 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumabmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinibmatched approximately | Major | Others | Coadministration of baricitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious… | 3 sources — open the full entry |
| Clozapinematched approximately | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 4 sources — open the full entry |
| Deferipronematched approximately | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Deucravacitinibmatched approximately | Major | Synergy | Coadministration of deucravacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Etanerceptmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumabmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximabmatched approximately | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomidematched approximately | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccinematched approximately | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Tofacitinibmatched approximately | Major | Others | Coadministration of tofacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious… | 1 sources — open the full entry |
| Upadacitinibmatched approximately | Major | Others | Coadministration of upadacitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious… | 1 sources — open the full entry |
| Yellow Fever Vaccinematched approximately | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Azathioprinematched approximately | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Denosumabmatched approximately | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the… | 2 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIBmatched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Diroximel Fumaratematched approximately | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may… | 1 sources — open the full entry |
| Hepatitis B Vaccine [rDNA]matched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Inactivated Hepatitis A vaccinematched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Lactobacillus Rhamnosus GGmatched approximately | Moderate | Others | Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms… | 11 sources — open the full entry |
| Ocrelizumabmatched approximately | Moderate | Synergy | The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of… | 1 sources — open the full entry |
| Roflumilast (Tablet)matched approximately | Moderate | Synergy | The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite… | 5 sources — open the full entry |
| Typhoid conjugate vaccinematched approximately | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Typhoid polysaccharide vaccinematched approximately | Moderate | Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 11 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin Ematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin Cmatched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Diphenhydramine Hydrochloride + Zinc Acetatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Ferrous Ascorbate + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Ferrous Sulfate + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Glycerin + Hypromellose + Polyethylene glycol + Tetrahydrozoline + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Naphazoline + Zinc Sulfatematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Tea tree oil + Echinacea + Geothermal watermatched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Tea Tree Oil + Geothermal Water + Vitamin Ematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Vitamin C + Vitamin Ematched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
| Vitamin C + Vitamin E + Lutein + Copper + Zincmatched approximately | Minor | Antagonism | Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat's claw, and zinc may antagonize the pharmacologic… | 4 sources — open the full entry |
Conditions
Conditions in which Anti-human T-lymphocyte immunoglobulin needs care, as documented in this source.
IMMUNE SUPPRESSION
ModerateDo not administer live vaccines to patients about to receive, receiving, or after treatment with lymphocyte immune globulin, anti-thy (equine). Concomitant administration of lymphocyte immune globulin, anti-thy (equine) with live virus vaccines carries a potential of uncontrolled viral replication in the immunosuppressed patient. There is insufficient information to fully define the extent of the risk, or the period of time during which the risk exists. If administered, live viruses may interfere with lymphocyte immune globulin, anti-thy (equine) treatment.
1 source
- "Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group (2010):
Liver Failure
ModerateThe use of lymphocyte immune globulin, anti-thy (equine) in patients with aplastic anemia and other hematologic abnormalities may result in abnormal tests of liver function (SGOT, SGPT, alkaline phosphatase) and renal function (serum creatinine). It is recommended to evaluate these tests closely in these patients.
1 source
- "Product Information. Atgam (lymphocyte immune globulin, anti-thy (equine))." Pfizer U.S. Pharmaceuticals Group (2010):